



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|-------------------------|-------------------------|--|
| (51) International Patent Classification 5 : C07D 491/16, A61K 31/395 | | A1 | (11) International Publication Number: WO 94/02485 (43) International Publication Date: 3 February 1994 (03.02.94) |
| (21) International Application Number: | PCT/US93/06679 | | (74) Agents: STERCHO, Yuriy, P. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). |
| (22) International Filing Date: | 16 July 1993 (16.07.93) | | |
| (30) Priority data: | 07/915,145 | 17 July 1992 (17.07.92) | US |
| (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM CORPORATION [US/US]; Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). | | | (81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). |
| (72) Inventors; and (75) Inventors/Applicants (for US only) : HOLT, Dennis, Alan [US/US]; 4450A Gebhart School Road, Mohnton, PA 19540 (US). LUENGO, Juan, Ignacio [ES/US]; 701 Pondview Drive, Audubon, PA 19403 (US). ROZAMUS, Leonard, Walter, Jr. [US/US]; 191 Drummers Lane, Wayne, PA 19087 (US). | | | Published <i>With international search report.</i> |

(54) Title: RAPAMYCIN DERIVATIVES**(57) Abstract**

Rapamycin derivatives; pharmaceutical compositions comprising such rapamycin derivatives and pharmaceutically acceptable carriers or diluents; and methods of using such derivatives to inhibit pathogenic fungi growth, inhibit immunosuppression or treat carcinogenic tumors are disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | FR | France | MR | Mauritania |
| AU | Australia | GA | Gabon | MW | Malawi |
| BB | Barbados | GB | United Kingdom | NE | Niger |
| BE | Belgium | GN | Guinea | NL | Netherlands |
| BF | Burkina Faso | GR | Greece | NO | Norway |
| BG | Bulgaria | HU | Hungary | NZ | New Zealand |
| BJ | Benin | IE | Ireland | PL | Poland |
| BR | Brazil | IT | Italy | PT | Portugal |
| BY | Belarus | JP | Japan | RO | Romania |
| CA | Canada | KP | Democratic People's Republic of Korea | RU | Russian Federation |
| CF | Central African Republic | KR | Republic of Korea | SD | Sudan |
| CG | Congo | KZ | Kazakhstan | SE | Sweden |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovak Republic |
| CM | Cameroon | LU | Luxembourg | SN | Senegal |
| CN | China | LV | Latvia | TD | Chad |
| CS | Czechoslovakia | MC | Monaco | TC | Togo |
| CZ | Czech Republic | MG | Madagascar | UA | Ukraine |
| DE | Germany | ML | Mali | US | United States of America |
| DK | Denmark | MN | Mongolia | UZ | Uzbekistan |
| ES | Spain | | | VN | Viet Nam |
| FI | Finland | | | | |

TITLE**RAPAMYCIN DERIVATIVES**

5

BACKGROUND OF THE INVENTION

This invention relates to rapamycin derivatives, pharmaceutical compositions comprising such derivatives, and methods of treatment of pathogenic fungi, methods of 10 inducing immunosuppression and methods of treating carcinogenic tumors utilizing such rapamycin derivatives.

Rapamycin is a naturally occurring macrocyclic triene antibiotic which can be produced by culturing an 15 organism in an aqueous nutrient medium. Its structure may be illustrated as follows:

20

25

30




Figure I

- 2 -

At least one rapamycin-producing strain of *Streptomyces hygroscopicus* was deposited with the Northern Utilization and Research Division, Agricultural Research Service, U.S. Department of Agriculture, 5 Peoria, Illinois, U.S.A. under accession number NRRL 5491. Rapamycin, and methods for its preparation by culturing NRRL 5491 are disclosed by U.S. Patent 3,929,992, issued December 30, 1975, the entire disclosure of which is hereby incorporated by reference.


10

SUMMARY OF THE INVENTION

This invention relates to novel rapamycin derivatives of the formula:

15

20



Formula II

wherein:

25 R¹ is selected from the group consisting of =O, (-OR⁶, H) and (H, H);

R² is selected from the group consisting of =O, (H, H), and (H, OH);

30 R³ and R⁶ are independently selected from the group consisting of -H, -C(=O)R⁷, -C(=O)OR⁷, -C(=O)NHR⁷, and

-C(=S)OR⁷;

35 R⁴ is selected from the group consisting of =O and (H, OR⁶); or R³ and R⁴ can be taken together to form a bridge of the formula A-C(R⁸)(R⁹)-O-B, where A is a bond to the oxygen bonded to the carbon at the 28-position and B is a bond to the carbon at the 30-

- 3 -

position;

R^5 is selected from the group consisting of -H and C_1 - C_4 alkyl;

5 R^7 is selected from the group consisting of C_1 - C_{10} alkyl, C_3 - C_6 cycloalkyl, aryl groups, and heterocyclic groups;

R^8 and R^9 are independently selected from the group consisting of H, C_1 to C_6 alkyl, or R^8 and R^9 taken together are =O;

10 provided that, when R^4 is =O, then R^2 is (H,OH); and all pharmaceutically acceptable salts, hydrates or solvates thereof.

15 This invention also relates to a pharmaceutical composition comprising an effective amount of one or more compounds of Formula II and a pharmaceutically acceptable carrier or diluent.


20 This invention also relates to a method of inhibiting the growth of pathogenic fungi in a human or other animal in need thereof which comprises administering an effective, non-toxic amount of one or more compounds of Formula II to such human or other animal.

25 This invention also relates to a method of inducing immunosuppression in a human or other animal in need thereof which comprises administering an effective, non-toxic amount of one or more compounds of Formula II to such human or other animal.

30 In addition, this invention relates to a method of treating carcinogenic tumors in a human or other animal comprising administering an effective, non-toxic amount of one or more compounds of Formula II to such human or other animal.

35 Still further, this invention relates to a method of preparing novel compounds of Formula II wherein R^4 is (H,OH) and R^1 , R^2 , R^3 , R^5 , R^6 , R^7 , R^8 , and R^9 are as described above, comprising contacting a compound of the formula

- 4 -



with a mixture of cerium trichloride and sodium cyanoborohydride.

15 **DETAILED DESCRIPTION OF THE INVENTION**

When any substituent or variable (e.g., aryl, alkoxyl, R¹, R², R³, R⁵, R⁶, etc.) occurs more than one time in the formula of any of the compounds of Formula II, such variable or substituent definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

20 Combinations of substituents and/or variables are in a constituent of the compounds of the invention are permissible only if such combinations result in a stable compound.

25 The parenthetical nomenclature used in the definition of substituents such as R¹ (e.g., (H, OR⁶) is intended to reflect the substituents on both valences of the relevant atom. The invention is not limited to particular isomers and the order of moieties in the parentheses does not suggest a particular configuration.

30 As used herein, except where otherwise noted, the term "alkyl" is intended to include both branched- and straight-chain saturated and unsaturated aliphatic hydrocarbon groups. Preferred alkyl groups have one to six carbon atoms, unless otherwise noted. Such alkyl group may be optionally substituted by one or more

members independently selected from the group consisting of aryl, hydroxyl, C₁-C₆ alkoxy, acyloxy, amino, N-acylamino, ketone, halogen, cyano and carboxyl. The term "alkyl" also includes the above-mentioned groups in which a heteroatom selected from oxygen, nitrogen and sulfur is substituted for one or more carbon atoms in the alkyl moiety.

As used herein, the term "aryl" is intended to include cyclic, heterocyclic, polycyclic and heteropolycyclic unsaturated C₄ to C₁₄ moieties, especially phenyl or naphthyl. Such aryl may be optionally substituted by one to five members independently selected from the group consisting of C₁-C₆ alkyl, aryl, hydroxyl, protected hydroxyl, C₁-C₆ alkoxy, acyloxy, amino, N-acylamino, -S(O)_n alkyl, nitro, cyano, carboxyl and halogen.

As used herein, the term "alkoxyl" represents an alkyl group as herein defined of the indicated number of carbon atoms attached through an oxygen bridge.

As used herein, the term "acyloxy" is intended to represent the groups -OC(O)-(alkyl) and -OC(O)-(aryl).

As used herein, the term "amino" is intended to represent the groups -NH₂, -N(alkyl)₂, -NH(alkyl), -N(aryl)₂, and -NH(aryl).

As used herein, the term "N-acylamino" is intended to represent the groups -NHC(O)-(alkyl) and -NHC(O)-(aryl).

As used herein, the term "ketone" is intended to mean the moiety -C(O)-.

As used herein, the term "halogen" is intended to include fluoro, chloro, bromo and iodo.

As used herein, the term "cycloalkyl" is intended to include saturated and unsaturated hydrocarbon aliphatic ring groups having the specified number of carbon atoms. Such cycloalkyl may be optionally substituted by one or more members

independently selected from the group consisting of aryl, hydroxyl, C₁-C₆ alkoxy, acyloxy, amino, N-acylamino, ketone, and halogen.

As used herein, the term "heterocycle" is intended to include a stable 5- to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms independently selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include but are not limited to piperidyl, piperidinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, furyl, and thienyl. The heterocycle may be optionally substituted in a manner such that carbon atoms attached to a heteroatom are not directly substituted by a heteroatom, by from one to four members independently selected from the group consisting of C₁-C₆ alkyl, aryl, hydroxyl, C₁-C₆ alkoxy, acyloxy, amino, N-acylamino, nitro and halogen.

Preferred compounds of the invention include the following compounds wherein, together or independently:

1. R¹ is (H,OH);
2. R² is (H,OH) or =O;
3. R³ is H;
4. R⁴ is =O or (H,OH); and
5. R⁵ is H or CH₃.

Specifically preferred compounds are the following:

1. R¹ is (H,OH), R² is =O, R³ is -H, R⁴ is (H,OH), and R⁵ is -H.

2. R¹ is (H,OH), R² is (H,OH), R³ is -H, R⁴ is (H,OH), and R⁵ is -H.

3. R¹ is (H,OH), R² is (H,OH), R³ is -H, R⁴ is =O, and R⁵ is -H.

5 4. R¹ is (H,OH), R² is (H,OH), R³ is -H, R⁴ is (H,OH), and R⁵ is -CH₃.

5. R¹ is (H,OH), R² is (H,H), R³ is H, R⁴ is (H,OH), and R⁵ is H.


The compounds of this invention can exist in
10 free form or, where appropriate, in salt form. Pharmaceutically acceptable salts and their preparation are well-known to those of skill in the art. The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts or the quaternary ammonium salts of such compounds which are formed, for example, from inorganic or organic acids of bases.

The compounds of the invention may form hydrates or solvates. It is known to those of skill in the art
20 that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent.

The compounds of this invention may be prepared
25 from rapamycin by the methods outlined below or conventional variations thereof. The reagents utilized are either described in the literature or are commercially available.

Rapamycin derivatives reduced at the C-30
30 position may be prepared by treatment of rapamycin with a mixture of cerium trichloride and sodium cyanoborohydride. Suitable solvents for this reaction include a mixture of acetic acid and tetrahydrofuran. This reaction is illustrated in Scheme A with rapamycin shown as the starting material; however other rapamycin derivatives may be reduced at the C-30 position using this method.


Scheme A



Compounds of the invention which are reduced at both the C-14 and C-30 positions (i.e., R^2 and $R^4 = (H, OH)$ may be prepared by the action of diisobutylaluminum hydride on rapamycin or a derivative thereof. By appropriate control of the same reduction method (limiting reaction times and amounts of reducing agent) compounds reduced only at the C-14 position can be prepared. This reaction is illustrated (reduction at both C-14 and C-30 positions shown), with rapamycin shown as the starting material, in Scheme B.

Scheme B

20



Also illustrated in Scheme B is the preparation of a C-13 O-methylated derivative, prepared by treatment with acidic methanol.


Compounds of the invention having a bridge between the C-28 and C-30 positions may be prepared by methods analogous to that shown in Scheme C. The C-30 reduced derivative is contacted with a dialkoxypropane such as dimethoxypropane to yield the desired compound where R^8 and R^9 are each methyl. Alternatively, the

reduced derivative is contacted with a ketal (e.g., $(CH_3O)_2CR^8R^9$).

Scheme C

5

10



15

Another type of compound having a bridge between the C-28 and C-30 positions may be prepared by methods analogous to that shown in Scheme D. The C-30 reduced derivative is contacted with carbonyldiimidazole to yield the desired compound where R^8 and R^9 taken together are =O.

Scheme D

20

25




30

Certain compounds of the invention may be prepared from novel phenylthionocarbonate intermediates. The preparation of these intermediates, and their conversion to compounds of the invention is illustrated in Scheme E. As shown in Scheme E, rapamycin (although a derivatized rapamycin could also be utilized) is contacted with phenylchlorothionoformate in the presence of a base such as dimethylaminopyridine (DMAP) to prepare rapamycin derivatized at C-28 and/or C-43 atoms. These intermediates may be converted to compounds of

- 10 -


this invention by reaction with a free-radical-based reductant such as trialkyltin hydride or tris(trimethylsilyl)silane and a radical initiator such as azobisisobutyronitrile (AIBN), benzoyl peroxide or 5 triethylborane.

Scheme E



Compounds of the invention with an oxy (=O) moiety at C-43 may be prepared as illustrated in Scheme F. Scheme F illustrates the preparation of 43-dehydrorapamycin, which is useful as an intermediate for preparing other compounds of the invention.

Scheme F



Compounds of the invention which are derivatized at C-28 may be prepared by contacting a compound where R⁵ is H with an appropriate acid chloride (e.g., R⁷C(O)Cl, 20 R⁷OC(O)Cl, R⁷NHC(O)Cl or R⁷OC(S)Cl) in the presence of a base such as dimethylaminopyridine.

The Examples provided below in this specification provide a variety of synthetic methods for preparing compounds of this invention.

25 This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and an effective amount of one or more compounds of Formula II.

A compound of Formula II is administered in 30 conventional dosage form prepared by combining a therapeutically effective amount of the compound ("active ingredient") with standard pharmaceutical carrier or diluents according to conventional procedures. These procedures may involve mixing, 35 granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

The pharmaceutical carrier employed may be, for

- 12 -

example, either a solid or liquid. Exemplary of solid carrier are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, 5 peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate along or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methylmethacrylate and the 10 like.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a 15 troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable solution or suspension in an 20 ampule or vial or nonaqueous liquid suspension.

To obtain a stable water soluble dosage form, a pharmaceutically acceptable salt of a compounds of the invention is dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3M solution of 25 succinic acid, or, preferably, citric acid.

Alternatively, acidic derivatives can be dissolved in suitable basic solutions. If a soluble salt form is not available, the compounds of the invention is dissolved in a suitable cosolvent or combinations thereof. 30 Examples of such suitable cosolvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0-60% of the total volume.

Tests indicate that the compounds of this 35 invention are useful in prophylactically or therapeutically inhibiting the growth of pathogenic fungi in a human or other animal in need thereof. The

invention, therefore, includes methods of inhibiting the growth of pathogenic fungi in a human or other animal in need thereof which comprises administering to such human or animal an effective, non-toxic amount of a compound 5 of Formula II.

By the term "pathogenic fungi" is meant fungi capable of producing disease in a human or other animal. Examples of pathogenic fungi include, but are not limited to *Candida albicans* and other candida species, 10 *Microsporum gypseum*, *Trichophyton mentagrophytes*, *Aspergillus* sp. and *Sporotrichum* sp. The ability of the compounds of this invention to inhibit the growth of pathogenic fungi may be demonstrated or predicted by standard tests known and used for this purpose, for 15 example, the yeast assay described hereinbelow.

One skilled in the art would be able, by routine experimentation, to determine what an effective, non-toxic amount of compound would be for the purpose of inhibiting pathogenic fungi growth. Generally, however, 20 an effective dosage will be in the range of about 0.05 to 100 milligrams per kilogram body weight per day.

Tests indicate that the compounds of this invention are also useful for inducing immunosuppression, i.e., inducing a suppression of a 25 human's or animal's immune system. This invention therefore relates to a method of prophylactically or therapeutically inducing immunosuppression in a human or other animal in need thereof which comprises administering an effective, non-toxic amount of such a 30 compound of this invention to such human or other animal.

The ability of the compounds of this invention to induce immunosuppression may be demonstrated in standard tests used for this purpose, for example, a 35 mixed lymphocyte reaction test or a test measuring inhibition of T-cell proliferation measured by thymidine uptake.

- 14 -

The fact that the compounds of this invention have utility in inducing immunosuppression means that they are useful in the treatment or prevention of resistance to or rejection of transplanted organs or 5 tissues (e.g., kidney, heart, lung, bone marrow, skin, cornea, etc.); the treatment or prevention of autoimmune, inflammatory, proliferative and hyperproliferative diseases, and of cutaneous manifestations of immunologically mediated diseases 10 (e.g., rheumatoid arthritis, lupus erythematosus, systemic lupus erythematosus, Hashimotos thyroiditis, multiple sclerosis, myasthenia gravis, type 1 diabetes, uveitis, nephrotic syndrome, psoriasis, atopical dermatitis, contact dermatitis and further eczematous 15 dermatitides, seborrheic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, Alopecia areata, etc.); the treatment of reversible obstructive airways disease, 20 intestinal inflammations and allergies (e.g., Coeliac disease, proctitis, eosinophilia gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis) and food related allergies (e.g., migraine, rhinitis, and eczema). 25

One skilled in the art would be able, by routine experimentation, to determine what an effective, non-toxic amount of compound would be for the purpose of inducing immunosuppression. Generally, however, an effective dosage will be in the range of about 0.05 to 30 100 milligrams per kilogram body weight per day.

The compounds of this invention should also be useful for treating carcinogenic tumors in a mammal. More specifically, the compounds should be useful for reducing tumor size, inhibiting tumor growth and/or 35 prolonging the survival time of tumor-bearing animals. Accordingly, this invention also relates to a method of treating carcinogenic tumors in a human or other animal

comprising administering to such human or animal an effective, non-toxic amount of a compound of Formula II. One skilled in the art would be able, by routine experimentation, to determine what an effective, non-
5 toxic amount of compound would be for the purpose of treating carcinogenic tumors. Generally, however, an effective dosage is expected to be in the range of about 0.05 to 100 milligrams per kilogram body weight per day.

The compounds of the invention may be
10 administered to a human or other animal in accordance with the aforementioned methods of treatment in an amount sufficient to produce such effect to a therapeutic or prophylactic degree. Such compound of the invention can be administered to such human or other
15 animal in a conventional dosage form prepared by combining the compound of the invention with a conventional pharmaceutically acceptable carrier or diluent according to known techniques. It will be recognized by one of skill in the art that the form and
20 character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.

The route of administration of the compound of
25 the invention may be oral, parenteral, by inhalation or topical. The term parenteral as used herein includes intravenous, intramuscular, subcutaneous, rectal, vaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral
30 administration are generally preferred.

The daily parenteral and oral dosage regimens for employing compounds of the invention to prophylactically or therapeutically inhibit the growth of pathogenic fungi, to prophylactically or
35 therapeutically induce immunosuppression, or to therapeutically treat carcinogenic tumors will generally be in the range of about 0.05 to 100, but preferably

about 0.5 to 10, milligrams per kilogram body weight per day.

The compounds of the invention may also be administered by inhalation. By "inhalation" is meant 5 intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. The preferred dosage amount of a compound of the invention to be 10 employed is generally within the range of about 10 to 100 milligrams.

The compounds of the invention may also be administered topically. By topical administration is meant non-systemic administration and includes the 15 application of a compounds of the invention externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream. By systemic administration is meant oral, 20 intravenous, intraperitoneal and intramuscular administration. The amount of a compound of the invention (hereinafter referred to as the active ingredient) required for therapeutic or prophylactic effect on pathogenic fungi growth inhibition or 25 immunosuppression induction upon topical administration will, of course, vary with the compound chosen, the nature and severity of the condition being treated and the animal undergoing treatment, and is ultimately at the discretion of the physician. A suitable topical 30 dose of a compound of the invention will generally be within the range of about 1 to 100 milligrams per kilogram body weight daily.

While it is possible for an active ingredient to be administered alone as the raw chemical, it is 35 preferable to present it as a pharmaceutical formulation. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g.,

from 1% to 2% by weight of the formulation although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.

5 The topical formulations of the present invention, both for veterinary and for human medical use, comprise an active ingredient together with one or more acceptable carrier(s) therefore and optionally any other therapeutic ingredient(s). The carrier(s) must be
10 "acceptable" in the sense of being compatible with the other ingredients of the formulation and no deleterious to the recipient thereof.

15 Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of where treatment is required such as: liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.

20 Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a
25 surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 90-100 C for half an hour. Alternatively, the solution may be sterilized by
30 filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate
35 (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be 5 prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor 10 oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided 15 or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis. The basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; 20 a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogols. The formulation may incorporate any 25 suitable surface active agent such as an anionic, cationic or non-ionic surface active such as sorbitan esters or polyoxyethylene derivatives thereof. Suspending agents such as natural gums, cellulose derivatives or in organic materials such as silicaceous 30 silicas, and other ingredients such as lanolin, may also be included.

It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of the compound of the invention will be 35 determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular animal being treated,

- 19 -

and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the compound of the invention 5 given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

Without further elaboration, it is believed that one skilled in the art can, using the preceding 10 description, utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

15

EXAMPLES

I. COMPOSITION EXAMPLES

EXAMPLE A - CAPSULE COMPOSITION

A pharmaceutical composition of this invention in the form of a capsule is prepared by filling a standard two-piece hard gelatin capsule with 50 mg of a compound of the invention, in powdered form, 100 mg of lactose, 25 32 mg of talc and 8 mg of magnesium stearate.

EXAMPLE B - INJECTABLE PARENTERAL COMPOSITION

A pharmaceutical composition of this invention in a form suitable for administration by injection is 30 prepared by stirring 1.5% by weight of a compound of the invention in 10% by volume propylene glycol and water. The solution is sterilized by filtration.

EXAMPLE C - OINTMENT COMPOSITION

35 Compound of the invention 1.0 g
White soft paraffin to 100.0 g
The compound of the invention is dispersed in a

- 20 -

small volume of the vehicle and gradually incorporated into the bulk of the vehicle to produce a smooth, homogeneous product. Collapsible metal tubes are then filled with the dispersion.

5

EXAMPLE D - TOPICAL CREAM COMPOSITION

Compound of the invention 1.0 g

Polawax GP 200 20.0 g

Lanolin Anhydrous 2.0 g

10

White Beeswax 2.5 g

Methyl hydroxybenzoate 0.1 g

Distilled Water to 100.0 g

15 The polawax, beeswax and lanolin are heated together at 60 C. A solution of methyl hydroxybenzoate is added and homogenization is achieved using high speed stirring. The temperature is then allowed to fall to 50 C. The compound of the invention is then added and dispersed throughout, and the composition is allowed to cool with slow speed stirring.

20

EXAMPLE E - TOPICAL LOTION COMPOSITION

Compound of the invention 1.0 g

Sorbitan Monolaurate 0.6 g

25

Polysorbate 20 0.6 g

Cetostearyl Alcohol 1.2 g

Glycerin 6.0 g

Methyl Hydroxybenzoate 0.2 g

Purified Water B.P. to 100.00 ml

30

The methyl hydroxybenzoate and glycerin are dissolved in 70 ml of the water at 75 . The sorbitan monolaurate, polysorbate 20 and cetostearyl alcohol are melted together at 75 C and added to the aqueous solution. The resulting emulsion is homogenized, allowed to cool with continuous stirring and the compound of the invention is added as a suspension in the remaining water. The whole suspension is stirred until

- 21 -

homogenized.

EXAMPLE F - EYE DROP COMPOSITION

Compound of the invention 0.5 g
5 Methyl Hydroxybenzoate 0.01 g
Propyl Hydroxybenzoate 0.04 g
Purified water B.P. to 100.00 ml (B.P.=British
Pharmacopia)

10 The methyl and propyl hydroxybenzoates are
dissolved in 70 ml purified water at 75 C and the
resulting solution is allowed to cool. The compound of
the invention is then added, and the solution is
sterilized by filtration through a membrane filter (0.22
mu m pore size) and packed aseptically into suitable
15 sterile containers.

**EXAMPLE G - COMPOSITION FOR ADMINISTRATION BY
INHALATION**

For an aerosol container with a capacity of 15-20
20 ml: Mix 10 mg of a compound of the invention with 0.2-
0.2% of a lubricating agent, such as polysorbate 85 or
oleic acid, and disperse such mixture in a propellant,
such as freon, preferably in a combination of (1,2
dichlorotetrafluoroethane) and difluorochloromethane and
25 put into an appropriate aerosol container adapted for
either intranasal or oral inhalation administration

**EXAMPLE H - COMPOSITION FOR ADMINISTRATION BY
INHALATION**

30 For an aerosol container with a capacity of 15-20
ml: Dissolve 10 mg of a compound of the invention in
ethanol (6- 8 ml), add 0.1-0.2% of a lubricating agent,
such as polysorbate 85 or oleic acid; and disperse such
in a propellant, such as freon, preferably a combination
35 of (1.2 dichlorotetrafluoroethane) and
difluorochloromethane, and put into an appropriate
aerosol container adapted for either intranasal or oral

- 22 -

inhalation administration.

II. SYNTHETIC EXAMPLES

5 In the following Examples, rapamycin was obtained via fermentation, and all other starting materials and chemical reagents were obtained from commercial suppliers unless otherwise indicated.

10 **Example 1. 14-Dihydrorapamycin**

(R¹ is (H,OH), R² is (H,OH), R³ is H, R⁴ is =O, and

R⁵ is H)

15 Rapamycin (45.7 mg, 0.05 mmol) in THF was treated with DIBAL (diisobutyl aluminum hydride) (0.2 mL of a 1 M THF solution, 0.20 mmol, slow dropwise addition) at -78° C under argon. The reaction mixture was stirred for 30 minutes and it was then quenched at -78° C with 6 mL of 1 N aqueous HCl. Ethyl acetate (40 mL) was added and 20 the layers were separated; the resulting organic extract was washed with 1 N aqueous HCl (6 mL), water (6 mL), brine (6 mL) and dried over anhydrous magnesium sulfate. The crude material was purified by prep HPLC (reversed phase, elution with 85:15 methanol/water). Recovered 25 rapamycin (19.2 mg, 42%) was isolated, along with material that was further purified by silica gel chromatography. Two 14- dehydrorapamycins, epimeric at C-14, were thus isolated in a 3:1 ratio.

30 Data for the major isomer: MS (ES⁺/NH₄OAc) *m/z* 938 (M+Na⁺), 933 (M+NH₄⁺), 884 (M+H-MeOH⁺), 866 (M+H-MeOH=H₂O⁺); MS (ES/NH₄COOH) *m/z* 960 (M+HCOO⁻), 914 (M-H⁻).

35 Data for the minor isomer: ¹H NMR (CDCl₃, 400 MHz): 6.403 (dd, *J* = 14.4, 10.8 Hz, 1 H), 6.281 (dd, *J* = 14.4, 10.2 Hz, 1H), 6.161 (d, *J* = 0.3 Hz, 1H), 5.160 (m, 1H), 4.406 (br s, 1H, H-14), 4.179 (d, *J* = 5.9 Hz, 1H), 3.789 (d, *J* = 5.9 Hz, 1H), 3.399 (s, 3H), 3.304 (s,

- 23 -

3H), 3.163 (s, 3H), 2.98-2.92 (m, 1H), MS (FAB/NaCl) *m/z* 938 (M + Na⁺); UV (MeOH) max 266, 277, 288 nm.

Example 2. 14,30-Bisdihydrorapamycin

5 (R¹ is (H,OH), R² is (H,OH), R³ is H, R⁴ is (H,OH), and R⁵ is H)

To a solution of rapamycin (91.4 mg, 0.10 nmol) in THF (5mL) was added DIBAL (1.0 mL of a 1 M THF solution, 1.0 mmol) at -78° C under argon. After 10 stirring at -78° C for 15 minutes, the reaction was quenched by addition of 10 mL of 1 N aqueous HCl at -78° C. The mixture was partitioned between ethyl acetate (70 mL) and brine (10 mL). The organic layer was washed with brine (10 mL), dried over anhydrous magnesium 15 sulfate and evaporated. Spectroscopic analysis showed this material to consist of a mixture of 14,28-bisdihydro- and 14-dihydro-rapamycins. Purification by prep HPLC (reversed phase, elution with 85:15 methanol/water) yielded two isomers of 14,28-bisdi- 20 hydrorapamycin. Data for each isomer: MS (FAB/NaCl) *m/z* 940 (M + Na); UV (MeOH) max 266, 277, 288 nm.

25

Example 3. 14,30-Bisdihydro-13-O-methylrapamycins

(R¹ is (H,OH), R² is (H,OCH₃), R³ is H, R⁴ is (H,OH) and R⁵ is H)

A solution of 14,30-dihydrorapamycins (15 mg) in 30 85:15 methanol/water was left standing in the freezer for 7 d. HPLC and TLC analysis showed the appearance of two new compounds. The solvent was evaporated in vacuo and the crude material was purified by flash chromatography (silica gel, gradient elution with 70:30 to 50:50 hexane/acetone) to yield two isomers of the title compound: minor-2.1 mg and major-3.8mg.

Data for the minor isomer: R_f (50:50 hexane/acetone) 0.38; ¹H NMR (CDCl₃, 400 MHz): 6.21-

6.17 (m, 2H), 6.09-6.03 (m, 1H), 5.823 (d, $J=8.7$ Hz, 1H), 5.631 (dd, $J=14.8$, 8.5Hz, 1H), 5.564 (d, $J=9.8$ Hz, 1H), 5.15-5.10 (m, 2H), 4.404 (d, $J=8.2$ Hz, 1H, H-14 becomes sharp singlet upon D_2O exchange), 4.207 (br d, 5 $J=6.8$ Hz, 1H), 3.835 (br d, $J=11.7$ Hz, 1H), 3.790 (dd, $J=9.4$, 6.1Hz, 1H), 3.542 (m, 1H, H-30, becomes a triplet, $J=5.5$ Hz upon D_2O exchange), 3.418 (s, 3H), 3.326 (s, 3H), 3.172 (dd, $J=6.8$, 5.5Hz, 1H, H-29), 3.137 (s, 3H), 3.086 (s, 3H), 2.98-2.92 (m, 1H), 2.800 (dd, 10 $J=17.1$, 5.5Hz, 1H), 2.696 (dd, $J=17.1$, 6.3Hz, 1H), 1.744 (d, $J=1.1$ Hz, 3H), 1.631 (s, 3H), 1.184 (d, $J=6.9$ Hz, 3H), 1.020 (d, $J=6.8$ Hz, 3H), 1.006 (d, $J=6.7$ Hz, 3H), 0.913 (d, $J=6.7$ Hz, 3H), 0.896 (d, $J=6.6$ Hz, 3H), 0.684 (q, $J=11.8$, 1H); MS (FAB/NaCl) m/z 954 ($M+Na^+$); UV 15 (MeOH) max 266, 277, 288 nm.

Data for the major isomer: R_f (50:50 hexane/acetone) 0.31; 1H NMR ($CDCl_3$, 400 MHz): 6.24-6.12 (m, 2H), 6.050 (dd, $J=14.8$, 9.6Hz, 1H), 5.835 (d, $J=9.3$ Hz, 1H), 5.674 (dd, $J=14.8$, 7.8Hz, 1H), 5.632 (d, 20 $J=10.1$ Hz, 1H), 5.20-5.14 (m, 1H), 5.143 (d, $J=4.6$ Hz, 1H), 4.418 (d, $J=7.6$ Hz, 1H, H-14, becomes sharp singlet upon D_2O exchange), 4.177 (br d, $J=5.6$ Hz, 1H), 3.874 (br d, $J=12.8$ Hz, 1H), 3.801 (dd, $J=6.2$, 3.3Hz, 1H), 3.614 (m, 1H, H-30, becomes a dd, $J=5.2$, 3.5Hz upon D_2O exchange), 3.421 (s, 3H), 3.419 (s, 3H), 3.145 (s, 3H), 3.092 (s, 3H), 2.98-2.92 (m, 1H), 2.769 (dd, $J=16.3$, 7.6Hz, 1H), 2.566 (dd, $J=16.3$, 4.1Hz, 1H), 1.741 (d, $J=0.9$ Hz, 3H), 1.630 (s, 3H), 1.177 (d, $J=6.9$ Hz, 3H), 1.051 (d, $J=6.7$ Hz, 3H), 1.000 (d, $J=6.3$ Hz, 3H), 0.966 (d, $J=6.8$ Hz, 3H), 0.908 (d, $J=6.7$ Hz, 3H), 0.693 (q, $J=11.9$, 1H); MS (FAB/NaCl) m/z 954 ($M+Na^+$); UV (MeOH) max 266, 277, 288 nm.

Example 4. 30-Dihydro-rapamycins

35 (R^1 is (H,OH), R^2 is = O, R^3 is H, R^4 is (H,OH) and R^5 is H)

Rapamycin (120 mg, 0.131 mmol) was dissolved in 2

mL of dry tetrahydrofuran under an argon atmosphere at room temperature. Cerium(III) chloride heptahydrate (390 mg, 1.05 mmol) was added, and the mixture was allowed to stir for 4 h. Acetic acid (15 μ L, 0.262 mmol) was then injected, and after a period of 5 min, sodium cyanoborohydride (9.0 mg, 0.143 mmol) was added. The resulting mixture was allowed to stir for 20 min, and then was deposited on a flash chromatography column containing silica gel. Elution with a 2% methanol/ 11% hexane/ 43% dichloromethane/ 44% ethyl acetate mobile phase yielded rapamycin (10 mg, R_f =0.42, M^+ =913) and two isomers of 30- dihydro-rapamycin (46 mg, R_f =0.38, M^+ =915) and (4.5 mg, R_f =0.35, M^+ =915).

15 **Example 5. 30-Dihydro-Rapamycin-28,30-Acetonide**
(R^1 is (H,OH), R^2 is =O, R^3 and R^4 are $-C-C(CH_3)_2$
-O-, and R^5 is H)

30-Dihydro-rapamycin (10 mg, 10.9 μ mol) was dissolved in 500 μ l of 2,2 dimethoxypropane. A small portion of Dowex 50X8-200 ion exchange resin was added, and the mixture was allowed to stir for 1h under an argon atmosphere at room temperature. The mixture was then deposited on a flash chromatography column. Elution with the above solvent system yielded the dioxane (4 mg, R_f =.078, M^+ =955).

15 **Example 6. 14-Desoxo-30(S)-dihydro-rapamycin**
(R^1 is (H,OH), R^2 is (H,H), R^3 is H, R^4 is (H,OH)
and R^5 is H)

30 30-Dihydro-rapamycin (15 mg, 16.4 μ mol) was dissolved in 2.0 mL of a 1:1 mixture of methanol and pyridine at room temperature. Hydrogen sulfide was allowed to bubble through the solution for 30 minutes, then the reaction mixture was sealed and allowed to stir for an additional 48 hours. Concentration followed by flash chromatography (eluting with 2% methanol/ 11% hexane/ 43% dichloromethane/ 44% ethyl acetate mobile

- 26 -

phase) yielded the title compound (12 mg); NMR: (δ TMS) 4.20 (d, $J=6$ Hz) H₂₈, 3.50 (d, $J=.3$ Hz) H₃₀, 3.20 (t, $J=6$ Hz) H₂₉.

5 **Example 7. Cyclic Carbonate of Dihydro-rapamycin**
(R¹ is (H,OH), R² is =O, R³ and R⁴ are -C-C(O)O-,
and R⁵ is H)

10 30-Dihydro-rapamycin (10 mg, 10.9 μ mol) is dissolved in 300 μ L of toluene under an argon atmosphere. N, N- Carbonyldiimidazole (5.3 mg, 33 μ mol) is added, and the mixture is allowed to stir for 24 h at 60° C. Flash chromatography of the mixture with the above solvent system provides the title compound.

15 **III. BIOLOGICAL EXAMPLES**

Compounds of the invention were analyzed for antifungal and immunosuppressive activity using the following assays.

20 **Assay for Antifungal Activity**

Yeast organism (*Saccharomyces cerevisiae*) in logarithmic growth were plated on complete agar medium (YPD). Compounds dissolved in an appropriate aqueous or organic solvent were placed in wells punched in the agar. Plates were incubated for 48 hours and zones of inhibition were measured. All of the compounds of the invention tested in this assay exhibited antifungal activity.

25 **Mitogenesis Assay for Immunosuppressive Activity**

30 Spleen cells from BDF1 female mice were established in RPMI with 10% fetal calf serum at 5 \times 10⁶/mL. One hundred mL aliquots of this suspension (5 \times 10⁵ cells) were dispensed into 96-well round-bottomed microtiter plates (Linbro, Flow Laboratories). Concanavalin A (5 μ g/ml) was added as the mitogenic stimulus, and the final volume in the microtiter wells was adjusted to 200 μ L with RPMI. Cell cultures were incubated for 72 hours at 37° C in a 5% CO₂ atmosphere

- 27 -

and pulsed with 0.5 μ Ci 3 H-thymidine (specific activity 2.00 Ci/mole) for the last 18 hours of the 72 hour culture. The cells were harvested on an automated multiple sample harvester and cell-associated 5 radioactivity counted in a Beckman liquid scintillation counter. The results are expressed as the mean values derived from quadruplicate measurements. Cell viability was determined by trypan blue exclusion after 72 hours of incubation. Compounds to be tested were added to the 10 microtiter plates at the appropriate dilutions prior to the addition of cells. All of the compounds of the invention tested in this assay exhibited immunosuppressive activity.

Results of these two assays, i.e., the antifungal 15 activity assay and the mitogenesis assay for immunosuppressive activity, for compounds of this invention are provided in Table 1.

Table 1
Biological Activities

| 5 | <u>Compound</u> | Yeast | Mitogenesis |
|----|----------------------|--------------------------------|-----------------------------|
| | | <u>IC₁₂ (Ng/mL)</u> | <u>IC₅₀ (nM)</u> |
| | Ex. 1*, major isomer | 13 | 10 |
| | Ex. 1, minor isomer | 20 | ND |
| | Ex. 2, isomer 1 | 40 | 1-10 |
| | Ex. 2, isomer 2 | 135 | 1-10 |
| 10 | Ex. 3, major isomer | 250 | 100-1000 |
| | Ex. 3, minor isomer | 235 | ND |
| | Ex. 4, isomer 1 | 6 | 2 |
| | Ex. 4, isomer 2 | 19 | 0.1-1 |
| | Ex. 5 | 3500 | 100-1000 |
| 15 | Ex. 6 | 180 | >1000 |

*Ex. means compound whose preparation is described by the indicated synthetic example of this disclosure.

ND=not determined

20 While the above descriptions and Examples fully describe the invention and the preferred embodiments thereof, it is understood that the invention is not limited to the particular disclosed embodiments coming within the scope of the following claims.

- 29 -

CLAIMS


What is claimed is:

1. A compound of the formula

5

10

15



wherein:

20 R¹ is selected from the group consisting of =0, (-OR⁶, H) and (H, H);

R² is selected from the group consisting of =0, (H, H), and (H, OH);

25 R³ and R⁶ are independently selected from the group consisting of -H, -C(=0)R⁷, -C(=0)OR⁷, -C(=0)NHR⁷, and

-C(=S)OR⁷;

30 R⁴ is selected from the group consisting of =0 and (H, OR⁶); or R³ and R⁴ can be taken together to form a bridge of the formula A-C(R⁸)(R⁹)-O-B, where A is a bond to the oxygen bonded to the carbon at the 28-position and B is a bond to the carbon at the 30-position;

35 R⁵ is selected from the group consisting of -H and C₁-C₄ alkyl;

R⁷ is selected from the group consisting of C₁-C₁₀ alkyl, C₃-C₆ cycloalkyl, aryl groups, and heterocyclic groups;

R^8 and R^9 are independently selected from the group consisting of H, C₁ to C₆ alkyl, or R^8 and R^9 taken together are =0;

5 provided that, when R^4 is =0, then R^2 is (H,OH); and all pharmaceutically acceptable salts, hydrates or solvates thereof.

10 2. A compound of Claim 1 where R^1 is (H,OH).

15 3. A compound of Claim 1 where R^2 is (H,OH).

4. A compound of Claim 1 where R^3 is H.

5. A compound of Claim 1 where R^4 is selected
15 from the group consisting of =0 and (H,OH).

20 6. A compound of Claim 1 where R^5 is H.

7. The compound of Claim 1 wherein:

20 (a) R^1 is (H,OH), R^2 is =0, R^3 is -H, R^4 is (H,OH), and R^5 is -H;

(b) R^1 is (H,OH), R^2 is (H,OH), R^3 is -H, R^4 is (H,OH), and R^5 is -H;

25 (c) R^1 is (H,OH), R^2 is (H,OH), R^3 is -H, R^4 is =0, and R^5 is -H;

(d) R^1 is (H,OH), R^2 is (H,OCH₃), R^3 is -H, R^4 is (H,OH), and R^5 is -H; or

(e) R^1 is (H,OH), R^2 is (H,H), R^3 is H, R^4 is (H,OH), and R^5 is H.

30 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and an effective therapeutic or prophylactic amount of one or more compounds of Claim 1.

35 9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an

effective therapeutic or prophylactic amount of one or more compounds of Claim 2.

10. A pharmaceutical composition comprising a 5 pharmaceutically acceptable carrier or diluent and an effective therapeutic or prophylactic amount of one or more compounds of Claim 3.

11. A pharmaceutical composition comprising a 10 pharmaceutically acceptable carrier or diluent and an effective therapeutic or prophylactic amount of one or more compounds of Claim 4.

12. A pharmaceutical composition comprising a 15 pharmaceutically acceptable carrier or diluent and an effective therapeutic or prophylactic amount of a compound of Claim 5.

13. A pharmaceutical composition comprising a 20 pharmaceutically acceptable carrier or diluent and an effective therapeutic or prophylactic amount of a compound of Claim 6.

14. A pharmaceutical composition comprising a 25 pharmaceutically acceptable carrier or diluent and an effective therapeutic or prophylactic amount of a compound of Claim 7.

15. A method of inhibiting the growth of 30 pathogenic fungi in a human or other animal in need thereof which comprises administering to such human or other animal an effective, non-toxic amount of a compound of Claim 1.


35 16. A method of inducing immunosuppression in a human or other animal in need thereof which comprises administering to such human or other animal an

effective, non-toxic amount of a compound of Claim 1.

17. A method of treating carcinogenic tumors in a human or other animal comprising administering to such 5 human or animal an effective, non-toxic amount of a compound of Claim 1.

18. A method of preparing a compound of Claim 1 wherein R⁴ is (H,OH) comprising contacting a compound of 10 the formula

15



wherein:

20 R¹ is selected from the group consisting of =O, (-OR⁶,H) and (H,H);

R² is selected from the group consisting of =O, (H,H), and (H,OH);

25 R³ and R⁶ are independently selected from the group consisting of -H, -C(=O)R⁷, -C(=O)OR⁷, -C(=O)NHR⁷, and

-C(=S)OR⁷;

R⁵ is selected from the group consisting of -H and C₁-C₄ alkyl;

30 R⁷ is selected from the group consisting of C₁-C₁₀ alkyl, C₃-C₆ cycloalkyl, aryl groups, and heterocyclic groups; and

R⁸ and R⁹ are independently selected from the group consisting of H, C₁ to C₆ alkyl, or R⁸ and R⁹ taken together are =O;

35

with a mixture of cerium trichloride and sodium cyanoborohydride.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/06679

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C07D 491/16; A61K 31/395

US CL :540/456; 514/183, 514/321

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 540/456; 514/183, 514/321

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | US, A, 5,102,876 (Caufield) 07 April 1992 See entire document. | 1-16 |
| Y | | 17-18 |
| X, P | US, A, 5,138,051 (Hughes et al.) | 1-16 |
| Y, P | 11 August 1992. See entire document. | 17-18 |
| Y | US, A, 5,100,883-(Schiehser) 31 March 1992 See entire document. | 17 |
| Y | US, A, 5,118,677 (Caufield) 02 June 1992 See entire document. | 17 |
| Y | US, A, 5,120,726 (Failli et al.) 09 June 1992. See entire document. | 17 |

 Further documents are listed in the continuation of Box C.

See patent family annex.

| | | |
|---|-----|--|
| * Special categories of cited documents: | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be part of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | | |
| *P* document published prior to the international filing date but later than the priority date claimed | | |

Date of the actual completion of the international search

16 AUGUST 1993

Date of mailing of the international search report

29 SEP 1993 *

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

MARIANNE CINTINS

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/06679

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| Y | Adv. Org. Chem., 1985, Jerry March, Dihydro-Addition, pgs. 691-699 & 809-814, esp. pg. 694. See entire document. | 18 |
| Y | Adv. Org. Chem., Part B, 1984, Carey et al, Reduction of Carbonyl Compounds, pgs. 199-213, esp. pgs. 204-205. See entire document. | 18 |

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claims 1-14, 15 & 18, drawn to Rapamycin derivatives, their method of use to inhibit growth of fungi, and a method for their synthesis, respectively, classified in Class 540, subclass 456 and Class 514, subclass 183.

Group II, claim 16, drawn to a method of inducing immunosuppression utilizing a Rapamycin derivative, classified in Class 514, subclass 183.

Group III, claim 17, drawn to a method of treating carcinogenic tumors utilizing a Rapamycin derivative, classified in Class 514, subclass 183.

PCT Rule 13.1 states that the international application shall relate to one invention only or to a group of inventions so linked as to form single general inventive concept ("requirement of unity of invention").

PCT Rule 13.2 states that unity of invention referred to Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.

Annex B, Part 1(c), further defines independent and dependent claims. Unity of invention only is concerned in relation to independent claims. Dependent claims are defined as a claim which contains all the features of another claim and is in the same category as the other claim. The category of a claim refers to the classification of claims according to subject matter, e.g. product, process, use, apparatus, means, etc.

Annex B, Part 1(e) indicates the permissible combinations of different categories of claims. Part 1(e(i)) states that inclusion of an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product, and an independent claim for a use of the said product is permissible.

Herein, two additional independent claims, i.e. 16 & 17, are included in the application, and appear contrary to PCT Rule 13.